Liver cancer mortality among male prison inmates in Texas, 1992-2003

Amy J. Harzke, Jacques Baillargeon, Karen J. Goodman, Sandi L. Pruitt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Prevalence estimates for several liver cancer risk factors-hepatitis C, hepatitis B, and history of alcohol abuse-are substantially higher in U.S. prison populations than in the general population. However, liver cancer mortality data from these populations are lacking. The primary aims of this study were to examine trends in liver cancer mortality rates from 1992 to 2003 among male prisoners in the Texas Department of Criminal Justice (TDCJ) and to compare these rates to general population rates. Methods: TDCJ data on male decedents (N = 4026) were linked with Texas Vital Statistics multiple-cause-of-death data. Crude average annual liver cancer death rates, average annual percent changes, and standardized mortality ratios were estimated. Results: Crude liver cancer death rates increased by an average annual 6.1% among male prisoners, which was considerably higher than the average annual percent change among similarly aged males in Texas (2.0%) and the U.S. (2.9%). The number of liver cancer deaths among male prisoners was 4.7 (4.0-5.6) and 6.3 (5.3-7.5) times higher than the expected number of deaths estimated using age-specific rates from these reference populations. Conclusions: From 1992 to 2003, liver cancer death rates and rate increases were elevated among Texas male prisoners. Findings support previous recommendations for targeted prevention, screening, and treatment of liver cancer risk factors in prison populations.

Original languageEnglish (US)
Pages (from-to)588-592
Number of pages5
JournalPreventive Medicine
Volume48
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Prisons
Liver Neoplasms
Prisoners
Mortality
Population
Criminal Law
Vital Statistics
Hepatitis C
Hepatitis B
Alcoholism
Cause of Death

Keywords

  • Cancer
  • Hepatitis
  • Incarceration
  • Liver diseases
  • Malignancies
  • Prison
  • Time trend

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Liver cancer mortality among male prison inmates in Texas, 1992-2003. / Harzke, Amy J.; Baillargeon, Jacques; Goodman, Karen J.; Pruitt, Sandi L.

In: Preventive Medicine, Vol. 48, No. 6, 06.2009, p. 588-592.

Research output: Contribution to journalArticle

Harzke, Amy J. ; Baillargeon, Jacques ; Goodman, Karen J. ; Pruitt, Sandi L. / Liver cancer mortality among male prison inmates in Texas, 1992-2003. In: Preventive Medicine. 2009 ; Vol. 48, No. 6. pp. 588-592.
@article{0390bc89684045ab9d80fcecc393d971,
title = "Liver cancer mortality among male prison inmates in Texas, 1992-2003",
abstract = "Objectives: Prevalence estimates for several liver cancer risk factors-hepatitis C, hepatitis B, and history of alcohol abuse-are substantially higher in U.S. prison populations than in the general population. However, liver cancer mortality data from these populations are lacking. The primary aims of this study were to examine trends in liver cancer mortality rates from 1992 to 2003 among male prisoners in the Texas Department of Criminal Justice (TDCJ) and to compare these rates to general population rates. Methods: TDCJ data on male decedents (N = 4026) were linked with Texas Vital Statistics multiple-cause-of-death data. Crude average annual liver cancer death rates, average annual percent changes, and standardized mortality ratios were estimated. Results: Crude liver cancer death rates increased by an average annual 6.1{\%} among male prisoners, which was considerably higher than the average annual percent change among similarly aged males in Texas (2.0{\%}) and the U.S. (2.9{\%}). The number of liver cancer deaths among male prisoners was 4.7 (4.0-5.6) and 6.3 (5.3-7.5) times higher than the expected number of deaths estimated using age-specific rates from these reference populations. Conclusions: From 1992 to 2003, liver cancer death rates and rate increases were elevated among Texas male prisoners. Findings support previous recommendations for targeted prevention, screening, and treatment of liver cancer risk factors in prison populations.",
keywords = "Cancer, Hepatitis, Incarceration, Liver diseases, Malignancies, Prison, Time trend",
author = "Harzke, {Amy J.} and Jacques Baillargeon and Goodman, {Karen J.} and Pruitt, {Sandi L.}",
year = "2009",
month = "6",
doi = "10.1016/j.ypmed.2009.03.011",
language = "English (US)",
volume = "48",
pages = "588--592",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Liver cancer mortality among male prison inmates in Texas, 1992-2003

AU - Harzke, Amy J.

AU - Baillargeon, Jacques

AU - Goodman, Karen J.

AU - Pruitt, Sandi L.

PY - 2009/6

Y1 - 2009/6

N2 - Objectives: Prevalence estimates for several liver cancer risk factors-hepatitis C, hepatitis B, and history of alcohol abuse-are substantially higher in U.S. prison populations than in the general population. However, liver cancer mortality data from these populations are lacking. The primary aims of this study were to examine trends in liver cancer mortality rates from 1992 to 2003 among male prisoners in the Texas Department of Criminal Justice (TDCJ) and to compare these rates to general population rates. Methods: TDCJ data on male decedents (N = 4026) were linked with Texas Vital Statistics multiple-cause-of-death data. Crude average annual liver cancer death rates, average annual percent changes, and standardized mortality ratios were estimated. Results: Crude liver cancer death rates increased by an average annual 6.1% among male prisoners, which was considerably higher than the average annual percent change among similarly aged males in Texas (2.0%) and the U.S. (2.9%). The number of liver cancer deaths among male prisoners was 4.7 (4.0-5.6) and 6.3 (5.3-7.5) times higher than the expected number of deaths estimated using age-specific rates from these reference populations. Conclusions: From 1992 to 2003, liver cancer death rates and rate increases were elevated among Texas male prisoners. Findings support previous recommendations for targeted prevention, screening, and treatment of liver cancer risk factors in prison populations.

AB - Objectives: Prevalence estimates for several liver cancer risk factors-hepatitis C, hepatitis B, and history of alcohol abuse-are substantially higher in U.S. prison populations than in the general population. However, liver cancer mortality data from these populations are lacking. The primary aims of this study were to examine trends in liver cancer mortality rates from 1992 to 2003 among male prisoners in the Texas Department of Criminal Justice (TDCJ) and to compare these rates to general population rates. Methods: TDCJ data on male decedents (N = 4026) were linked with Texas Vital Statistics multiple-cause-of-death data. Crude average annual liver cancer death rates, average annual percent changes, and standardized mortality ratios were estimated. Results: Crude liver cancer death rates increased by an average annual 6.1% among male prisoners, which was considerably higher than the average annual percent change among similarly aged males in Texas (2.0%) and the U.S. (2.9%). The number of liver cancer deaths among male prisoners was 4.7 (4.0-5.6) and 6.3 (5.3-7.5) times higher than the expected number of deaths estimated using age-specific rates from these reference populations. Conclusions: From 1992 to 2003, liver cancer death rates and rate increases were elevated among Texas male prisoners. Findings support previous recommendations for targeted prevention, screening, and treatment of liver cancer risk factors in prison populations.

KW - Cancer

KW - Hepatitis

KW - Incarceration

KW - Liver diseases

KW - Malignancies

KW - Prison

KW - Time trend

UR - http://www.scopus.com/inward/record.url?scp=67349245167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349245167&partnerID=8YFLogxK

U2 - 10.1016/j.ypmed.2009.03.011

DO - 10.1016/j.ypmed.2009.03.011

M3 - Article

VL - 48

SP - 588

EP - 592

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

IS - 6

ER -